FDA-cleared profile

AI-CVD

HeartLung Corporation · CT/CTA · FDA-cleared (510(k))

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Clinical role
Opportunistic quantitative CT measurement and clinician-review support across the labeled AI-CVD modules.
Images and patients
CT/CTA · Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Key limitation
Keep in mind: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat Input: DICOM CT studies, including noncontrast thoracic CT, CAC studies, contrast CCTA or CTPA, and labeled abdomen or pelvis examinations.
  • Who uses it?Intended users: Trained physicians and qualified healthcare professionals who review quantitative CT measurements.
  • What does the software produce?Output: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.
  • What is its most important limitation?Key limitation: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.

Clinical takeaway. Clinical role: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Opportunistic quantitative CT measurement and clinician-review support across the labeled AI-CVD modules.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM CT studies, including noncontrast thoracic CT, CAC studies, contrast CCTA or CTPA, and labeled abdomen or pelvis examinations.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital and outpatient CT, cardiac, vascular, pulmonary, and preventive-care workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians and qualified healthcare professionals who review quantitative CT measurements.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Prospective clinical studies were not required to demonstrate the safety and effectiveness of the device. Instead, clinical validation studies were performed based upon retrospective analyses". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Prospective clinical studies were not required to demonstrate the safety and effectiveness of the device. Instead, clinical validation studies were performed based upon retrospective analyses". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252029 FDA evidence package for AI-CVD

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationChest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
  • Scopeexact submission
  • Tested versionAI-CVD
  • IndependenceSponsor or vendor study

K252029

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K252029; no exact native submission identifier match was found.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT studies, including noncontrast thoracic CT, CAC studies, contrast CCTA or CTPA, and labeled abdomen or pelvis examinations.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252029: AI-CVD

  2. Routing

    Source context, not route validation: DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252029: AI-CVD

  3. AI processing

    Source context, not route validation: The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K252029: AI-CVD

  4. Returned objects

    Source context, not route validation: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K252029: AI-CVD

  5. Viewer/worklist/report

    Unresolved route: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K252029: AI-CVD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Only trained physicians and qualified healthcare professionals who review quantitative ct measurements. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K252029 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K252029 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K252029 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252029
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
11Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 11 PubMed titles and one trial record. Several titles use AI-CVD as a study label, but none states the tested AI-CVD software release or K252029; the trial is unrelated, so all 12 candidates are quarantined. The current discovery snapshot contains 11 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252029: AI-CVD

    U.S. Food and Drug Administration - Published 2025-12-19 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AI-CVD® model card (K252029)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K252029 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K233209

uOmnispace.CT

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uOmnispace.CT is software for viewing, manipulating, evaluating, and analyzing medical images within healthcare institutions. The FDA indication lists colon visualization, dental panoramic and paraxial reconstruction, lung and airway segmentation and quantitative parameters, nodule analysis, vessel and brain-perfusion analysis, heart and coronary analysis, calcium scoring, dynamic analysis, bone-structure labeling, liver evaluation, dual-energy processing, and cardiovascular combined analysis.

Modality
CT/CTA
Anatomy
Colon, jaw, lungs, airways, brain, heart, vessels, liver, spine, ribs, and other labeled CT regions
Decision
2024-05-17
FDA-cleared K242624

Medical Image Post-processing Software (uOmnispace.CT)

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.

Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Decision
2025-05-14
FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history